InvestorsHub Logo
Followers 240
Posts 11825
Boards Moderated 0
Alias Born 08/14/2003

Re: None

Saturday, 09/08/2018 7:49:22 PM

Saturday, September 08, 2018 7:49:22 PM

Post# of 999
This stock was mentioned to me and got my immediate attention when I saw it dealt with GVHD. I'm 3+ years post stem cell transplant and was on anti rejection drugs for some time after the initial transplant for PH+ ALL. I had some rejection issues, but none that I considered that serious, but my Dr. may have had greater concerns. I have been hospitalized post stem cells with things like shingles, pneumonia, and a catheter infection, again, I didn't feel that sick, but they erred on the side of caution.

I don't know if a cannabis based drug for GVHD would have made my recovery any better, but I would have tried it if it was available, and my Dr. had agreed. I did note that he was referenced for a paper he'd had a part in writing in the presentation linked on the company website. I've let him know about it and he planned to look into it.

Someone mentioned a planed Phase 3, can anyone tell me what's happening, or provide a link if it's on the clinical trials database. Even with insurance the meds for GVHD were among the most expensive drugs I took, though my costs weren't very high. I don't know that they'd be any cheaper if covered by insurance but cannabis based, but if insurance didn't apply the cannabis based product would certainly be more expensive.

I'm now down to seeing my Dr. 4 times a year unless I'm having some complication, each time he's still looking at certain things for a sign that I'm having a rejection issue. I don't know if cannabis will have benefits there, but I do take a small amount of it to help with muscle aches I get from taking the chemo, the generic for Gleevec, that I'm continuing on. I don't know that they'll ever recommend stopping the drug, but on special occasions I'm permitted to go off it for short periods and the muscle aches practically disappear.

I welcome any information before I invest, I'm still looking at the company.

Gary